Discovering chronic pain treatments: better animal models might help us get there

Enhanced facial grimacing when laparotomy involves cutaneous and visceral tissue injury

Introduction

Laparotomy is a common surgical procedure that entails incision of the abdomen and is associated with varying degrees of postoperative pain. Laparotomies can be performed in mice and result in facial grimacing, which can be quantified using PainFace, a software platform that automates facial grimace analyses.

Objectives

We evaluated the extent to which incision of the ventral skin, peritoneum, and intestinal manipulation, all of which can occur as part of a laparotomy surgery, affects the magnitude and duration of facial grimacing in 2 strains of mice along with allodynia at the incision site in CD-1 mice.

Methods

White-coated CD-1 male and female mice and black-coated C57BL/6 male mice (8-12 weeks of age) were split into groups (n = 20 per group) that underwent laparotomies with varying manipulations.

Results

Mouse grimace scale scores were higher in both strains after surgery when the small intestine was manipulated in 2 different ways compared to groups that received a cutaneous incision alone or cutaneous and peritoneal incision.

Conclusion

These studies show that mice exhibit more pronounced facial grimacing when both cutaneous and visceral tissues are injured during laparotomy surgery. Consistent with clinical findings, our experiments suggest that postoperative pain could be reduced by minimizing visceral tissue injury during surgical procedures.

Is chronic pain caused by central sensitization? A review and critical point of view

Chronic pain causes disability and loss of health worldwide. Yet, a mechanistic explanation for it is still missing. Frequently, neural phenomena, and among them, Central Sensitization (CS), is presented as causing chronic pain. This narrative review explores the evidence substantiating the relationship between CS and chronic pain: four expert researchers were divided in two independent teams that reviewed the available evidence. Three criteria were established for a study to demonstrate a causal relationship: (1) confirm presence of CS, (2) study chronic pain, and (3) test sufficiency or necessity of CS over chronic pain symptoms. No study met those criteria, failing to demonstrate that CS can cause chronic pain. Also, no evidence reporting the occurrence of CS in humans was found. Worryingly, pain assessments are often confounded with CS measures in the literature, omitting that the latter is a neurophysiological and not a perceptual phenomenon. Future research should avoid this misconception to directly interrogate what is the causal contribution of CS to chronic pain to better comprehend this problematic condition.

Advancing Pain Understanding and Drug Discovery: Insights from Preclinical Models and Recent Research Findings

Despite major advancements in our understanding of its fundamental causes, pain-both acute and chronic-remains a serious health concern. Various preclinical investigations utilizing diverse animal, cellular, and alternative models are required and frequently demanded by regulatory approval bodies to bridge the gap between the lab and the clinic. Investigating naturally occurring painful disorders can speed up medication development at the preclinical and clinical levels by illuminating molecular pathways. A wide range of animal models related to pain have been developed to elucidate pathophysiological mechanisms and aid in identifying novel targets for treatment. Pain sometimes drugs fail clinically, causing high translational costs due to poor selection and the use of preclinical tools and reporting. To improve the study of pain in a clinical context, researchers have been creating innovative models over the past few decades that better represent pathological pain conditions. In this paper, we provide a summary of traditional animal models, including rodents, cellular models, human volunteers, and alternative models, as well as the specific characteristics of pain diseases they model. However, a more rigorous approach to preclinical research and cutting-edge analgesic technologies may be necessary to successfully create novel analgesics. The research highlights from this review emphasize new opportunities to develop research that includes animals and non-animals using proven methods pertinent to comprehending and treating human suffering. This review highlights the value of using a variety of modern pain models in animals before human trials. These models can help us understand the different mechanisms behind various pain types. This will ultimately lead to the development of more effective pain medications.

Making sense of feelings

Internal feeling states such as pain, hunger, and thirst are widely assumed to be drivers of behaviours essential for homeostasis and animal survival. Call this the 'causal assumption'. It is becoming increasingly apparent that the causal assumption is incompatible with the standard view of motor action in neuroscience. While there is a well-known explanatory gap between neural activity and feelings, there is also a disjuncture in the reverse direction-what role, if any, do feelings play in animals if not to cause behaviour? To deny that feelings cause behaviours might thus seem to presage epiphenomenalism-the idea that subjective experiences, including feelings, are inert, emergent and, on some views, non-physical properties of brain processes. Since epiphenomenalism is antagonistic to fundamental commitments of evolutionary biology, the view developed here challenges the standard view about the function of feelings without denying that feelings have a function. Instead, we introduce the 'sense making sense' hypothesis-the idea that the function of subjective experience is not to cause behaviour, but to explain, in a restricted but still useful sense of 'explanation'. A plausible framework is derived that integrates commonly accepted neural computations to blend motor control, feelings, and explanatory processes to make sense of the way feelings are integrated into our sense of how and why we do and what we do.

Research Progress on Effects of Ginsenoside Rg2 and Rh1 on Nervous System and Related Mechanisms

Neurological-related disorders are diseases that affect the body's neurons or peripheral nerve tissue, such as Parkinson's disease (PD) and Alzheimer's disease (AD). The development of neurological disorders can cause serious harm to the quality of life and functioning of the patient. The use of traditional therapeutic agents such as dopamine-promoting drugs, anticholinergic drugs, cholinesterase inhibitors, and NMDA receptor antagonists is often accompanied by a series of side effects such as drug resistance, cardiac arrhythmia, liver function abnormalities, and blurred vision. Therefore, there is an urgent need to find a therapeutic drug with a high safety profile and few side effects. Herbal medicines are rich in active ingredients that are natural macromolecules. Ginsenoside is the main active ingredient of ginseng, which has a variety of pharmacological effects and is considered to have potential value in the treatment of human diseases. Modern pharmacological studies have shown that ginsenosides Rg2 and Rh1 have strong pharmacological activities in the nervous system, with protective effects on nerve cells, improved resistance to neuronal injury, modulation of neural activity, resistance to cerebral ischemia/reperfusion injury, improvement of brain damage after eclampsia hemorrhage, improvement of memory and cognitive deficits, treatment of AD and vascular dementia, alleviation of anxiety, pain, and inhibition of ionic-like behavior. In this article, we searched the pharmacological research literature of Rg2 and Rh1 in the field of neurological diseases, summarized the latest research progress of the two ginsenosides, and reviewed the pharmacological effects and mechanisms of Rg2 and Rh1, which provided a new way of thinking for the research of the active ingredients in ginseng anti-neurological diseases and the development of new drugs.